|1.||Monge, Luis: 3 articles (01/2014 - 06/2011)|
|2.||Fernández, Nuria: 3 articles (01/2014 - 06/2011)|
|3.||Granado, Miriam: 2 articles (01/2014 - 08/2012)|
|4.||Carreño-Tarragona, Gonzalo: 2 articles (01/2014 - 08/2012)|
|5.||Diéguez, Godofredo: 2 articles (08/2012 - 06/2011)|
|6.||García-Villalón, Angel Luis: 2 articles (08/2012 - 06/2011)|
|7.||Yu, Yi: 1 article (12/2015)|
|8.||Zhu, Huiqin: 1 article (12/2015)|
|9.||Wang, Chuang: 1 article (12/2015)|
|10.||Wang, Qinwen: 1 article (12/2015)|
05/01/2007 - "Given the efficacy of clopidogrel, which blocks the G(i/o)-coupled P2Y purinoceptor 12, as an antiplatelet/antithrombotic drug, our data suggest that specifically blocking only PAR1-mediated G(i/o) signaling could also be an effective therapeutic approach with the possibility of less unwanted bleeding."
06/25/2011 - "These results suggest that the coronary relaxation to Ap4A is reduced after ischemia-reperfusion, and that this reduction may be due to impaired effects of KATP channels and to reduced response of purinergic P2Y receptors."
08/01/2012 - "These results suggest that Ap3A induces coronary vasodilation, an effect attenuated by ischemia-reperfusion due to the functional impairment of purinergic P2Y receptors and K(ATP) channels, and/or reduced nitric oxide release. "
01/01/2014 - "To determine the involvement of purinergic receptors in coronary endothelium-dependent relaxation, the response to acetylcholine (1 × 10(-8) to 3 × 10(-7)M) was recorded in isolated rat hearts perfused according to the Langendorff procedure before and after 30 min of ischemia and 15 min of reperfusion and after the inhibition of nitric oxide synthesis with L-NAME (10(-4)M), in the absence and presence of the antagonist of purinergic P2X receptors, PPADS (3 × 10(-6)M), and of the antagonist of purinergic P2Y receptors, Reactive Blue 2 (3 × 10(-7)M). "
11/25/2004 - "The G protein-coupled P2Y purinoceptors have wide physiological functions, but their role(s) in tumor progression remain unclear. "
11/01/2005 - "In addition, we have uncovered several GPCRs, such as neuropeptide receptors, adenosine A2B receptor, P2Y purinoceptor, calcium-sensing receptor and metabotropic glutamate receptors, that are expressed at a significantly higher level in some cancer tissue and may play a role in cancer progression. "
08/01/1993 - "The mechanism of the unimpaired relaxant effect of ATP in the Watanabe heritable hyperlipidemic rabbit aorta was investigated to elucidate the involvement of P2y purinoceptor at the endothelial level during atherosclerosis. "
08/01/1993 - "The maintained endothelial relaxant effect of ATP and ADP is therefore not due to activation of P1 or P2y purinoceptors but may involve activation of a remodeled purinergic receptor site that emerges with the progression of atherosclerosis. "
|5.||Ganglion Cysts (Ganglion)
|2.||Adenosine Triphosphate (ATP)
|3.||GTP-Binding Proteins (G-Protein)
|4.||Nitric Oxide (Nitrogen Monoxide)
|5.||Purinergic P2X Receptors
|8.||Adenosine A2B Receptor
|9.||NG-Nitroarginine Methyl Ester (L-NAME)
|10.||Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)